BMO Capital Markets Initiates Coverage on Astera Labs (NASDAQ:ALAB)

Analysts at BMO Capital Markets started coverage on shares of Astera Labs (NASDAQ:ALAB) in a note issued to investors on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $375.00 price target on the stock. BMO Capital Markets‘s price objective would indicate a potential upside of 67.96% from the stock’s current price.

ALAB has been the topic of a number of other reports. Citigroup downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Friday, October 9th. Needham & Company LLC decreased their price objective on shares of Astera Labs from $425.00 to $300.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings lowered shares of Astera Labs from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, October 23rd. TD Cowen dropped their target price on Astera Labs from $300.00 to $225.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Roth Capital reissued a “buy” rating and set a $450.00 target price on shares of Astera Labs in a report on Wednesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Astera Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $320.85.

Astera Labs Stock Down 4.4%

Shares of NASDAQ ALAB opened at $223.27 on Thursday. Astera Labs has a fifty-two week low of $97.89 and a fifty-two week high of $499.48. The firm’s 50-day simple moving average is $304.94 and its 200 day simple moving average is $255.78. The stock has a market cap of $38.73 billion, a P/E ratio of 88.95 and a beta of 3.85.

Astera Labs (NASDAQ:ALAB) last announced its earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.13. The firm had revenue of $584.90 million during the quarter, compared to analyst estimates of $550.78 million. Astera Labs had a net margin of 29.64% and a return on equity of 27.30%. Astera Labs’s revenue was up 153.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 EPS. On average, sell-side analysts anticipate that Astera Labs will post 2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jitendra Mohan sold 90,630 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $340.35, for a total transaction of $30,845,920.50. Following the completion of the sale, the chief executive officer directly owned 1,266,665 shares of the company’s stock, valued at $431,109,432.75. This represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Sanjay Gajendra sold 90,630 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $340.35, for a total transaction of $30,845,920.50. Following the sale, the chief operating officer owned 1,119,038 shares of the company’s stock, valued at $380,864,583.30. The trade was a 7.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 396,059 shares of company stock worth $123,408,470. 10.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Greenleaf Trust lifted its position in Astera Labs by 1.8% in the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock worth $966,000 after buying an additional 36 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Astera Labs by 74.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock valued at $46,000 after buying an additional 41 shares during the period. Integrated Advisors Network LLC grew its holdings in shares of Astera Labs by 4.8% during the 3rd quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock valued at $350,000 after acquiring an additional 45 shares in the last quarter. Interchange Capital Partners LLC grew its holdings in shares of Astera Labs by 4.4% during the 3rd quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock valued at $423,000 after acquiring an additional 50 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in shares of Astera Labs by 2.7% during the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock valued at $209,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Strong quarter and outlook: Q3 revenue reached a record $584.9 million, up 153.6% year over year, while EPS of $1.32 beat estimates. Scorpio X-Series switches drove growth, and the company forecast Q4 revenue of $730 million to $750 million, citing AI connectivity demand. Astera Labs Q3 Earnings Beat Estimate on Scorpio X-Series Strength
• Positive Sentiment: Some analysts remain bullish: Northland upgraded ALAB to Outperform with a $315 target, and Morgan Stanley raised its target to $389 while retaining an Overweight rating. Astera Labs Upgraded to Outperform at Northland Securities
• Neutral Sentiment: Director Michael Hurlston resigned from Astera Labs’ board; the announcement did not provide a reason. Astera Labs Director Resigns from Board
• Negative Sentiment: Valuation and estimate concerns are weighing on the stock: Shares fell despite the earnings beat, as investors focused on ALAB’s rich valuation and analysts’ forecast reductions. TD Cowen cut its target to $225 and rated the stock Hold; Susquehanna lowered its target to $258 and moved to Neutral. Rising costs, competition—including Marvell’s optical push—and reliance on a limited number of customers add to the risks. Astera Labs Stock Drops After Q3 Results Spotlight Rich Valuation

About Astera Labs

Astera Labs, Inc is a semiconductor and connectivity solutions company that develops hardware and software for data centers, cloud computing, and artificial intelligence infrastructure. Its products are designed to help move data between processors, memory, storage, and networking components while addressing bandwidth, latency, and system-management requirements.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) Smart Retimers, Taurus Ethernet Smart Cable Modules, Scorpio Smart Fabric Switches, and Leo CXL Memory Connectivity Controllers.